Phase I Clinical Trial of DS-7423

Phase 1

• Conditions: Advanced solid tumors not curable with, or not eligible for standard treatment(s)

• Registration Number: JPRN-jRCT2080221724
• Lead Sponsor: DAIICHISANKYO Co.,Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-29
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 27

Inclusion Criteria

Histologically or cytologically diagnosed advanced solid tumors which are not curable with, or not eligible for standard treatment(s)
- ECOG performance status: 0-1

Exclusion Criteria

- History of any of the following events within 6 months prior to start of study treatment
myocardial infraction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident or cerebral infraction, pulmonary embolism, deep vein thrombosis, or other clinically significant thromboembolic event, clinically significant pulmonary disease (eg severe COPD or asthma)
- History of type I and II diabetes
- Patient with a clinically active brain metastasis, or who need drugs to control adverse event
- History of pneumonitis
- Patients with any severe or uncontrolled intercurrent diseases

Study & Design

• Study Type: Interventional
• Study Design: Not specified